TeneoTwo Enters into Agreement to be Acquired by AstraZeneca
Gunderson Dettmer is representing client TeneoTwo, a developer of therapeutic antibodies, in its pending acquisition by AstraZeneca, a bio-pharmaceutical company that focuses on the discovery, development and commercialization of prescription medicine. AstraZeneca will acquire TeneoTwo’s TNB-486, a Phase I clinical-stage CD19/CD3 T-cell engager, which will help accelerate the development of a new medicine for B-cell malignancies.
In the announcement of the acquisition, Senior Vice President of AstraZeneca Anas Younes said, “By redirecting the body’s natural immune response to target B-cell malignancies, TNB-486 alone or in combination with CD20-targeted therapy could potentially deepen clinical responses and improve patient outcomes. We believe this innovative molecule, which was designed to optimize the therapeutic window of T-cell activation, will enable us to explore novel combinations that have the potential to become new standards of care in this setting.”
The Gunderson Dettmer deal team was co-led by partner Michael Irvine and associates Nate Gray and Julie Mahoney, and included of counsel Craig Olshan and associates Brenden Glapion, Scout Moran, Alex Lee and Shawn Trabanino.